DR REDDYS LABORATORIES Financial Statement Analysis
|
||
The Revenues of DR REDDYS LABORATORIES have increased by 14.50% YoY .
The Earnings Per Share (EPS) of DR REDDYS LABORATORIES has increased by 23.60 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
DR REDDYS LABORATORIES Last 5 Annual Financial Results
[BOM: 500124|NSE : DRREDDY]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹24,670 Cr | ₹21,545 Cr | ₹19,048 Cr | ₹17,517 Cr | ₹15,448 Cr |
Expenses | ₹18,321 Cr | ₹17,778 Cr | ₹15,178 Cr | ₹15,047 Cr | ₹12,270 Cr |
Operating Profit (Excl OI) | ₹6,349 Cr | ₹3,767 Cr | ₹3,870 Cr | ₹2,470 Cr | ₹3,178 Cr |
Other Income | ₹1,056 Cr | ₹485 Cr | ₹291 Cr | ₹621 Cr | ₹338 Cr |
Interest | ₹143 Cr | ₹96 Cr | ₹97 Cr | ₹98 Cr | ₹89 Cr |
Depreciation | ₹1,250 Cr | ₹1,165 Cr | ₹1,229 Cr | ₹1,163 Cr | ₹1,135 Cr |
Profit Before Tax | ₹6,049 Cr | ₹3,061 Cr | ₹2,884 Cr | ₹1,886 Cr | ₹2,336 Cr |
Profit After Tax | ₹4,507 Cr | ₹2,183 Cr | ₹1,952 Cr | ₹2,026 Cr | ₹1,950 Cr |
Consolidated Net Profit | ₹4,507 Cr | ₹2,183 Cr | ₹1,952 Cr | ₹2,026 Cr | ₹1,950 Cr |
Earnings Per Share (Rs) | ₹334.41 | ₹270.55 | ₹131.16 | ₹117.28 | ₹121.90 |
PAT Margin (%) | 19.91 | 18.27 | 10.13 | 10.25 | 11.57 |
ROE(%) | 21.76 | 21.36 | 11.93 | 11.82 | 13.76 |
ROCE(%) | 26.86 | 26.22 | 14.59 | 15.49 | 11.12 |
Total Debt/Equity(x) | 0.07 | 0.06 | 0.18 | 0.17 | 0.14 |
Key Financials |
||
Market Cap | : | ₹ 93,256.7 Cr |
Revenue (TTM) | : | ₹ 31,229.3 Cr |
Net Profit(TTM) | : | ₹ 5,428.6 Cr |
EPS (TTM) | : | ₹ 65.1 |
P/E (TTM) | : | 17.2 |
Industry Peers & Returns | 1W | 1M | 1Y |
DR REDDYS LABORATORIES | -3% | -6.5% | -12.7% |
SUN PHARMACEUTICAL INDUSTRIES | -3% | -8.7% | 4.1% |
DIVIS LABORATORIES | -4.7% | -4.5% | 58.5% |
CIPLA | -4.3% | -3.2% | -3.2% |
TORRENT PHARMACEUTICALS | -3% | -12.3% | 13.8% |
MANKIND PHARMA | -1.6% | -8% | 9.4% |
ZYDUS LIFESCIENCES | -1% | -8.1% | -5.9% |
LUPIN | NA | -7.7% | 16.6% |
AUROBINDO PHARMA | -5.2% | -10.5% | 3.3% |
DR REDDYS LABORATORIES Revenues
[BOM: 500124|NSE : DRREDDY]
Y-o-Y | 14.50 % |
5 Yr CAGR | 12.41 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹24,670 Cr | 14.50 | |
Mar2023 | ₹21,545 Cr | 13.11 | |
Mar2022 | ₹19,048 Cr | 8.74 | |
Mar2021 | ₹17,517 Cr | 13.39 | |
Mar2020 | ₹15,448 Cr | - |
DR REDDYS LABORATORIES Operating Profit
[BOM: 500124|NSE : DRREDDY]
Y-o-Y | 68.52 % |
5 Yr CAGR | 18.89 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹6,349 Cr | 68.52 | |
Mar2023 | ₹3,767 Cr | -2.65 | |
Mar2022 | ₹3,870 Cr | 56.65 | |
Mar2021 | ₹2,470 Cr | -22.27 | |
Mar2020 | ₹3,178 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 47.17 % |
5 Yr CAGR | 5.77 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 25.74% | 47.17 | |
Mar2023 | 17.49% | -13.93 | |
Mar2022 | 20.32% | 44.11 | |
Mar2021 | 14.1% | -31.45 | |
Mar2020 | 20.57% | - |
DR REDDYS LABORATORIES Profit After Tax
[BOM: 500124|NSE : DRREDDY]
Y-o-Y | 106.52 % |
5 Yr CAGR | 23.30 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹4,507 Cr | 106.52 | |
Mar2023 | ₹2,183 Cr | 11.83 | |
Mar2022 | ₹1,952 Cr | -3.67 | |
Mar2021 | ₹2,026 Cr | 3.90 | |
Mar2020 | ₹1,950 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 8.98 % |
5 Yr CAGR | 14.53 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 19.91 % | 8.98 | |
Mar2023 | 18.27 % | 80.36 | |
Mar2022 | 10.13 % | -1.17 | |
Mar2021 | 10.25 % | -11.41 | |
Mar2020 | 11.57 % | - |
DR REDDYS LABORATORIES Earnings Per Share (EPS)
[BOM: 500124|NSE : DRREDDY]
Y-o-Y | 23.60 % |
5 Yr CAGR | 28.70 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹334 | 23.60 | |
Mar2023 | ₹271 | 106.27 | |
Mar2022 | ₹131 | 11.83 | |
Mar2021 | ₹117 | -3.79 | |
Mar2020 | ₹122 | - |
DR REDDYS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 500124|NSE : DRREDDY]
Y-o-Y | 2.44 % |
5 Yr CAGR | 24.67 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 26.86% | 2.44 | |
Mar2023 | 26.22% | 79.71 | |
Mar2022 | 14.59% | -5.81 | |
Mar2021 | 15.49% | 39.30 | |
Mar2020 | 11.12% | - |
DR REDDYS LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹1,117.7 |
Current MarketCap | : | ₹ 93,256.7 Cr |
Updated EOD on | : | Feb 28,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
DR REDDYS LABORATORIES | -3% |
-6.5% |
-12.7% |
SENSEX | -3.4% |
-4.4% |
0.6% |
DR REDDYS LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | -2.1% | -3.2% | -0.6% |
BSE LOW VOLATILITY INDEX | -3.5% | -4.7% | -4.1% |
BSE 100 ESG INDEX | -3.6% | -4% | 2.1% |
BSE SENSEX 50 | -3.7% | -4.7% | -0.5% |
BSE SENSEX SIXTY | -3.7% | -4.7% | NA |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 50 | -3.4% | -4.5% | 0% |
NIFTY 100 | -4% | -5.1% | -0.8% |
NIFTY LOW VOLATILITY 50 | -4.1% | -5% | 1.3% |
NIFTY50 EQUAL WEIGHT | -4.1% | -4.7% | -1.6% |
NIFTY QUALITY LOW-VOLATILITY 30 | -4.2% | -6.5% | -4% |
You may also like the below Video Courses
FAQ about DR REDDYS LABORATORIES Financials
How the annual revenues of DR REDDYS LABORATORIES have changed ?
The Revenues of DR REDDYS LABORATORIES have increased by 14.50% YoY .
How the Earnings per Share (EPS) of DR REDDYS LABORATORIES have changed?
The Earnings Per Share (EPS) of DR REDDYS LABORATORIES has increased by 23.60 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs